| Biomarker ID | 1138 |
| PMID | 23737455 |
| Year | 2013 |
| Biomarker | Maltotriose |
| Biomarker Basis | Concentration Based |
| Biomolecule | Metabolites |
| Source | Tissue |
| Subjects | Humans |
| Regulation | Decreased in Patients with Recurrence |
| Odds Ratio/Hazard Ratio/Relative Risk | HR: 0.29 (95% CI: 0.13–0.71) |
| Effect on Pathways | NA |
| Experiment | Recurrence Free Survival Vs No Recurrence Free Survival |
| Type of Biomarker | Prognostic |
| Cohort | Matched malignant and nonmalignant prostatectomy samples from 95 PCa patients were taken for the study. Data was available for 93 patients |
| Senstivity | NA |
| Specificity | NA |
| AUC | NA |
| Accuracy | NA |
| Level Of Significance | p =0.006 |
| Method Used | gas chromatography-mass spectrometry (GC-MS) and liquid chromatography-mass spectrometry (LC-MS/MS) analysis |
| Clinical | No |
| Remarks | Univariate Analysis; Done between patients with Maltotriose <0.129 and Maltotriose ≥ 0.129 |
| Clinical Trial Number | NA |
| Degree Of Validity | Not validated on independent patient dataset |
| Technical Name | NA |